fda warning bpc-157 peptide 2024 2025 panel on peptides will include experts who promote the unproven chemicals favored by RFK Jr Regulatory Alert: FDA's April 2026

As a physician dedicated to regenerative and musculoskeletal medicine, I deeply value scientific innovation and remain enthusiastic about future breakthroughs in this area

If the injection is needed (e.g., to replete B or B in a deficient mother), it can be used, but the infant should be observed for any unusual symptoms (though none would be expected from B vitamins, apart from perhaps looser stools if anything)

R., Guan, X

Each individual will experience a different sensation during a B12 injection

What payers require for Zepbound prior authorization Zepbound PA requirements are typically more stringent: Documented BMI of 30 or greater, or 27 or greater with at least one weight-related comorbidity Evidence of lifestyle intervention including documented participation in diet, exercise, and behavioral modification programs (usually for at least 3 to 6 months) Prior medication trials (some plans require documented failure of other weight management medications before approving tirzepatide) Specialist involvement (some plans require referral to or management by a bariatric medicine specialist, endocrinologist, or obesity medicine physician) Ongoing weight monitoring documentation with specific weight loss targets (typically 5% of baseline weight within 3 to 6 months of starting therapy) Patients researching BMI requirements for GLP-1 medications should understand that these thresholds directly correspond to the prior authorization criteria their provider must document

intensive care needs to be taken with any type of sterile water used for reconstitution